Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administrationcleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)-based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%-75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%-81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%-58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5-1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing. FIGURE 2. Overall survival estimates by Kaplan-Meier based on each assay. Favorable and unfavorable results were dichotomized based on absent versus present detection of CTCs by AdnaTest and direct detection RT-PCR (DDPCR) and by enumeration of <5 versus ≥5 cells/7.5 mL of blood by CellSearch assay.
M ultiple blood-based assays to detect circulating tumor cells (CTCs) and tumor cell products are in different phases of development, for different contexts of use. These contexts include assessing prognosis, predicting drug sensitivity to therapeutics to guide treatment selection, and as response indicators to assess efficacy. Few assays have undergone the rigorous analytical validation that is required before the evidence generation to establish clinical validity and utility for a specific context of use can proceed. [1] [2] [3] At present, only 1 CTC assay, CellSearch (Janssen Diagnostics, Raritan, NJ), has achieved the level of a US Food and Drug Administration clearance. This assay uses an immunomagnetic ferrofluid to capture epithelial cell adhesion molecule 1 (EpCAM)positive cells and reports the number of cells that meet defined criteria. 4, 5 The enumeration result represents a subset of the CTCs in blood that can be reproducibly identified and scored across laboratories and investigators and has been shown to be prognostic for survival before and after treatment. 6 More recently, the enumeration biomarker in combination with lactate dehydrogenase was shown to satisfy the Prentice criteria for a surrogate endpoint, with respect to survival at the individual patient level in metastatic castration-resistant prostate cancer (mCRPC). 7 A limitation of the CellSearch assay is low CTC detection rates at key decision points in management. Needed are assays to detect cells at a higher frequency in a higher percentage of patients. 2, 5, [8] [9] [10] [11] AdnaTest (AdnaGen AG, Langenhagen, Germany) is a positive selection assay that captures cells using immunomagnetic beads coated by antibodies to surface markers. The captured cells are detected using a polymerase chain reaction (PCR)-based method that measures specific transcripts based on tumor type: epidermal growth factor receptor (EGFR), carcinoembryonic antigen, and EpCAM for colon cancer, 12 and MUC-1, human epidermal growth factor receptor 2 (HER2), and GA733-2 for breast cancer, with detection sensitivities similar to that of CellSearch. 13, 14 The AdnaTest for mCRPC detects CTCs based on KLK3, prostatespecific membrane antigen (PSMA), or EGFR transcripts. 15 More recently, a modified platform has been used to detect truncated forms of androgen receptor (AR) as a tumor sensitivity biomarker in mCRPC. [16] [17] [18] Previously, we developed and analytically validated a nonselection-based direct detection reverse transcription PCR (DDPCR) CTC assay for KLK2, KLK3, HOXB13, GRHL2, and FOXA1, genes that are highly expressed in prostate tissue relative to white blood cells. The assay is performed on blood samples collected in PAXgene tubes that stabilize intracellular RNA, requires minimal on-site processing, and can be stored and shipped for future analysis at a central laboratory. Relative to CellSearch enumeration, the DDPCR assay was shown to provide a more reliable and robust prediction of overall survival. 19 Here, we report the analytical validation and performance characteristics of the AdnaTest Prostate Cancer CTC assay and compare AdnaTest to the CellSearch and DDPCR assays for the context of use of detecting CTCs in mCRPC.
PATIENTS AND METHODS

Patients and Samples
Blood samples were studied from 47 men with progressive mCRPC (both before and after chemotherapy) per Prostate Cancer Working Group guidelines, 20 treated at Memorial Sloan Kettering Cancer Center between November 2011 and October 2013. Blood was collected at the time of phlebotomy performed as part of their routine clinical management. Samples for each assay were drawn at the same time and processed in the Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center. Duplicate patient samples were obtained to assess the reproducibility of the AdnaTest assay. Control samples were obtained from 12 volunteers without evidence of prostate cancer. Signed informed consent was obtained from all patients and volunteers on an institutional review board-approved protocol.
Assays
The AdnaTest was performed on 10 mL of whole blood collected into a lavender-top EDTA tube that was immediately placed on ice, for processing within 4 hours of blood draw. The test is a 2-step procedure to capture CTCs from whole blood using magnetic beads conjugated with antibodies for EpCAM and HER2 and analyzed for expression of prostate-specific genes KLK3, PSMA, and EGFR. The AdnaTest result was considered positive if at least 1 tumor-associated transcript measured more than 0.1 ng/μL (controls were always performed concurrently with each sample analysis). Analytical validity was established using a previously described method 8 (Supplemental Digital Content, http://links.lww.com/PPO/A22).
The DDPCR assay was performed as previously described. In brief, whole blood was collected in 2.5-mL PAXgene tubes and transported at room temperature to the laboratory, and then frozen at −80°C until analyzed. 19 This assay was considered positive if at least 1 of the following transcripts was detected: KLK3, KLK2, HOXB13, GRHL2, and FOXA1.
CellSearch CTC enumeration was performed on 7.5 mL of blood collected in CellSave tubes, according to the US Food and Drug Administration-cleared manufacturer's method. 4 The results are reported as unfavorable (≥5) or favorable (≤4) number of cells per 7.5 mL of blood.
Data Reporting/Statistical Methods
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RESULTS
The clinical characteristics for the 55 samples provided by the 47 patients are presented in Table 1 . Forty-five (82%) of those samples were provided by patients who have since died; median survival was 13 months (range, 1-42 months).
Sample Collection, Processing, and Analysis
A standard operating protocol was generated for sample collection, processing, and analysis for each of the tests, summarized in Table 2 .
Detection Rates of AdnaTest, DDPCR, and CellSearch With Cross-Test Comparisons
AdnaTest specificity was established using blood from 12 healthy volunteers: it was set at 1.0 as no prostate-expressed genes were detected in any of the volunteer samples tested. The AdnaTest was positive in 34 of the 55 patient samples evaluated (62%; 95% confidence interval [CI], 48%-75%) ( Table 2) . Overall, AdnaTest detected 3 transcripts in 4 samples, 2 transcripts in 12 samples, and 1 transcript in 18 samples (Table 3 ). KLK3 was detected in 33 (97%) of the positive samples; EGFR alone was detected in 1 sample without KLK3 detection. The addition of PSMA transcript (detected in 17 samples, all with KLK3 detection) did not increase the sensitivity of the test.
The DDPCR assay was positive in 38 samples (69%; 95% CI, 55%-81%) based on the detection of 1 or more genes (Table 2) . Overall, the DDPCR assay detected 5 transcripts in 12 samples, 4 transcripts in 8 samples, 3 transcripts in 3 samples, 2 transcripts in 8 samples, and 1 transcript in 7 samples (Table 3 ). KLK3 was detected in 31 of 55 samples (56%; 95% CI, 43%-69%); of these 31 samples, 17 With CellSearch, unfavorable counts (≥5 cells/7.5 mL of blood) were found in 25 of the 55 samples (45%; 95% CI, 33%-58%), of which 23 were positive based on the AdnaTest, and 24 were positive by DDPCR (Table 3 ). Favorable/"negative" counts (≤4 cells/7.5 mL of blood) were found in 30 samples (55%; 95% CI, 42%-67%), with 0 cells detected in 20 samples (33%; 95% CI, 19%-51%) and 1 to 4 cells detected in 10 samples (67%; 95% CI, 49%-81%). For these 30 samples with favorable CellSearch CTC counts, AdnaTest was positive in 11 (37%; 95% CI, 22%-54%), whereas DDPCR was positive in 14 (47%; 95% CI, 29%-65%).
The detection rates of AdnaTest, DDPCR assays, and CellSearch unfavorable counts are summarized in Figure 1 .
Concordance Between Assays
The concordance between CTC detection by AdnaTest and DDPCR in whole blood and CTC enumeration by CellSearch is shown in Table 3 , highlighting discordant results for any given sample. There were 5 samples with a positive AdnaTest who had no prostate transcripts detected by the DDPCR in whole blood, whereas 9 samples with DDPCR-detected prostate transcripts in whole blood had a negative AdnaTest. The AdnaTest and DDPCR were concordant in 41 samples (75%), of which 29 had detectable cells with both assays, and 12 samples had no cells detected with either assay.
The level of agreement between the 3 assays, based on the positive/negative dichotomization, was compared using McNemar test (Fig. 1 ). There was significant disagreement between DDPCR and CellSearch (P = 0.001) and the AdnaTest and CellSearch (P = 0.027). We did not find a disagreement between the AdnaTest and DDPCR (P = 0.423).
Estimates of the Concordance Probability of the Assays to Predict Survival
These results are based on the 47 patients. The concordance probability estimates are 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Figure 2 shows the Kaplan-Meier overall survival estimates for the 3 assays, grouping patients by positive/negative results for each assay. Predictions of survival times were similar between the assays.
DISCUSSION
Generating the evidence to demonstrate the utility of a biomarker for a specific context of use begins by establishing the analytical validity of the assay, which includes how the specimen is acquired proceeding through transport to the laboratory and processing, and ending with the method of reporting of the results. Circulating tumor cell detection rates in this population of men with progressive mCRPC were similar between the AdnaTest Prostate assay, which identifies CTC based on the presence of KLK3, PSMA, or EGFR transcripts, and the DDPCR assay for the presence of prostate-specific KLK2, KLK3, HOXB13, GRHL2, and FOXA1 transcripts. Both were more sensitive than CellSearch, which uses an EpCAM-based CTC capture method. Predictions of survival times, however, were similar between the assays, using the positive/negative and unfavorable/favorable reporting criteria for each test.
All 3 of the assays-AdnaTest, DDPCR, and CellSearchhave now met the criteria for analytical validation. Direct detection reverse transcription PCR required the lowest blood volume, minimal on-site processing, and the longest stability for batch processing. Both the AdnaTest and DDPCR assays detect prostatespecific transcripts not usually detected in nucleated blood cells. AdnaTest detection in this population was based on KLK3 transcripts in 33 of 34 samples: the addition of PSMA and EGFR detection did not increase sensitivity significantly. With the DDPCR, KLK3 was detected in 31 of 38 positive samples. The additional 7 positive samples were found with KLK2 in 4 samples, FOXA1 alone in 2 samples, and with HOXB13 alone in 1 sample; GRHL2 did not add to detection sensitivity. Importantly, the DDPCR approach is more flexible than AdnaTest, easily enabling inclusion of additional genes.
There are also novel assays currently being evaluated that are designed to detect AR splice variants and ligand-binding domain mutations associated with resistance to AR-directed therapies. 18, 22 A phase III registration trial was recently initiated comparing galeterone to enzalutamide for patients shown to have ARv7-positive CTCs detected using a modified AdnaTest (NCT02438007). However, this trial was discontinued early based on recommendations of the data monitoring committee determining it was unlikely to meet its primary endpoint of improving radiographic progression-free survival. 23 A separate validation of the ability to detect treatment-specific alterations in AR will be required before they can be tested prospectively in the clinic.
Practical issues favor the DDPCR assay. AdnaTest and CellSearch require more blood, which can be an issue when multiple tubes of blood are needed for routine safety assessments and to determine antitumor effects. There are also advantages to the PAXgene tubes used with the DDPCR assay, which require minimal on-site processing and can be transported to a central laboratory at room temperature up to several days after the blood draw for freezing and storage for future analysis. The CellSearch tubes provide consistent results up to 72 hours from the time of blood draw if a stable temperature is maintained. With AdnaTest, the time from blood draw to analysis is critical, as samples must be transported on ice from the phlebotomy site for processing in 4 hours or less. These differences in the time from blood draw to analysis and the amount of on-site processing required affect scalability of the tests.
One limitation of our current analysis is the cohort size. While our data showed KLK3 detection to be the primary marker for AdnaTest-and DDPCR-positive results, replication of these results would be needed before considering removing the lessuseful transcripts from those tests.
In conclusion, the DDPCR and CellSearch assays confer easier use in practice than AdnaTest. Importantly, the AdnaTest and DDPCR assays had detection rates similar to each other, and both were superior to the CellSearch detection rate.
